Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter，Single-arm, Phase II Clinical Study of Icotinib for IIIA - IIIB NSCLC Patients With Epidermal Growth Factor Receptor Mutation

NCT02820116 is registered in ClinicalTrials.gov with Beijing Haidian Hospital as lead sponsor.

NCT NCT02820116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02820116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter，Single-arm, Phase II Clinical Study of Icotinib for IIIA - IIIB NSCLC Patients With Epidermal Growth Factor Receptor Mutation
Lead sponsor
Beijing Haidian Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2016
Completion date
April 30, 2023
Enrollment
67 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer(nsclc)